166 related articles for article (PubMed ID: 32421352)
1. Correlation between Ivacaftor-induced CFTR Activation in Airway Epithelial Cells and Improved Lung Function: A Proof-of-Concept Study.
Debley JS; Barrow KA; Rich LM; Singh P; McKone EF; Nichols DP
Ann Am Thorac Soc; 2020 Aug; 17(8):1024-1027. PubMed ID: 32421352
[No Abstract] [Full Text] [Related]
2. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.
Sermet-Gaudelus I
Eur Respir Rev; 2013 Mar; 22(127):66-71. PubMed ID: 23457167
[TBL] [Abstract][Full Text] [Related]
3. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
[TBL] [Abstract][Full Text] [Related]
4. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
Hayes D; Long FR; McCoy KS; Sheikh SI
Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
[No Abstract] [Full Text] [Related]
5. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
Kotha K; Clancy JP
Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
[TBL] [Abstract][Full Text] [Related]
6. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
7. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
[TBL] [Abstract][Full Text] [Related]
8. Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.
Yousef S; Solomon GM; Brody A; Rowe SM; Colin AA
Chest; 2015 Mar; 147(3):e79-e82. PubMed ID: 25732475
[TBL] [Abstract][Full Text] [Related]
9. Pulmonology: CFTR modulators for cystic fibrosis.
Bertoncini E; Colomb-Lippa D
JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
[No Abstract] [Full Text] [Related]
10. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
11. Ivacaftor for patients with cystic fibrosis.
Wainwright CE
Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
[TBL] [Abstract][Full Text] [Related]
12. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
13. The bidirectional relationship between CFTR and lipids.
Cottrill KA; Farinha CM; McCarty NA
Commun Biol; 2020 Apr; 3(1):179. PubMed ID: 32313074
[TBL] [Abstract][Full Text] [Related]
14. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.
Fohner AE; McDonagh EM; Clancy JP; Whirl Carrillo M; Altman RB; Klein TE
Pharmacogenet Genomics; 2017 Jan; 27(1):39-42. PubMed ID: 27636560
[No Abstract] [Full Text] [Related]
15. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
17. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
[TBL] [Abstract][Full Text] [Related]
18. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
20. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.
Bellin MD; Laguna T; Leschyshyn J; Regelmann W; Dunitz J; Billings J; Moran A
Pediatr Diabetes; 2013 Sep; 14(6):417-21. PubMed ID: 23952705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]